Penumbra Inc.: Thrombectomy Business Expansion As a Significant Driver For Overall Market Share Growth! 

Penumbra’s second quarter results reflect significant execution across multiple areas, showing both strengths and challenges that contribute to the overall investment thesis for the company. The company’s revenue reached $339.5 million, a 13.4% increase year-over-year on a reported basis and 12.7% in constant currency, highlighting strong underlying growth. This growth was driven by robust performance in the U.S. thrombectomy business, especially in the venous thromboembolism (VTE) sector, which saw an impressive 42% year-over-year growth, due to adoption of innovative products like the Flash 2.0 and Bolt 12.